DYNE THERAPEUTICS INC (DYN) Stock Analyst Ratings
USA - NASDAQ:DYN - US26818M1080 - Common Stock
24.29 USD
+0.12 (+0.5%)
24.29 USD
0 (0%)
ChartMill assigns a Buy % Consensus number of 83% to DYN. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 35.99. This target is 48.17% above the current price.
DYN was analyzed by 20 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about DYN.
In the previous month the buy percentage consensus was at a similar level.
DYN was analyzed by 20 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-10-10 | Oppenheimer | Downgrade | Outperform -> Perform |
| 2025-08-25 | Raymond James | Upgrade | Outperform -> Strong Buy |
| 2025-08-06 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-07-31 | Stifel | Maintains | Buy -> Buy |
| 2025-07-29 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-07-29 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-07-29 | Raymond James | Reiterate | Outperform -> Outperform |
| 2025-07-15 | JP Morgan | Maintains | Neutral -> Neutral |
| 2025-06-26 | Jones Trading | Initiate | Buy |
| 2025-06-18 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-06-18 | Baird | Maintains | Outperform -> Outperform |
| 2025-06-17 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-05-09 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-05-09 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-03-21 | JP Morgan | Maintains | Neutral -> Neutral |
| 2025-03-17 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-03-17 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-12 | BMO Capital | Initiate | Outperform |
| 2025-03-07 | ScotiaBank | Initiate | Sector Outperform |
| 2025-02-28 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-02-28 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-02-28 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-01-24 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-01-14 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2025-01-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-10 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-01-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-13 | Baird | Initiate | Outperform |
| 2024-11-26 | RBC Capital | Initiate | Outperform |
| 2024-11-13 | Chardan Capital | Maintains | Buy -> Buy |
DYNE THERAPEUTICS INC / DYN FAQ
What do analysts expect the price target to be for DYNE THERAPEUTICS INC (DYN)?
20 analysts have analysed DYN and the average price target is 35.99 USD. This implies a price increase of 48.17% is expected in the next year compared to the current price of 24.29.
What is the consensus rating for DYN stock?
The consensus rating for DYNE THERAPEUTICS INC (DYN) is 83 / 100 . This indicates that analysts generally have a positive outlook on the stock.
What is the number of analysts for DYN stock?
The number of analysts covering DYNE THERAPEUTICS INC (DYN) is 20.